Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-altering therapeutics for rare and often fatal genetic lipid disorders. Its lead product in Phase III clinical development, lomitapide, is a small molecule, oral therapy to treat severe lipid disorders for an orphan patient population. Lomitapide has demonstrated the lowering of both bad cholesterol (LDL-C) and triglyceride (TG) levels in patients with a rare form of hypercholesterolemia. The company plans to initiate a clinical program to treat patients with a severe genetic form of hypertriglyceridemia called familial chylomicronemia (FC). Aegerion Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Bridgewater, New Jersey.